Abbvie Inc.

Abbott Laboratories Corporation

Abbvie Bahamas Limited

Tammie K Jinkerson

Mark A Matulenko

Ryan G Keddy

David A DeGoey

Charles W Hutchins

Warren M Kati

Pamela L Donner

Kevin R Woller

John T Randolph

Allan C Krueger

Sachin V Patel

Christopher E Motter

Lissa T Nelson

John K Pratt

Rolf Wagner

Todd Warren Rockway

Dachun Liu

Arthur Gomtsyan

David A Betebenner

Douglas K Hutchinson

Clarence J Maring

Charles A Flentge

Michael D Tufano

Yi Gao

Kathy A Sarris

Seble H Wagaw

Wenke Li

Mary E Bellizzi

Daniel D Caspi

William A Carroll

Chih-hung Lee

Jerome F Daanen

Michael E Kort

Jean C Califano

John R Koenig

Brian S Brown

Philip R Kym

Derek W Nelson

Robert G Schmidt

Marlon D Cowart

Michael J Dart

Meena V Patel

Bo Liu

Erol K Bayburt

Marc J Scanio

Andrew Bogdan

Eric A Voight

Steven P Latshaw

Brian D Wakefield

Hillary M Peltier

Jean-Christophe C Califano

David A Degoey

Sean Colm Turner

Clara I Villamil

Anil Vasudevan

Gregory A Gfesser

Jennifer M Frost

Sridhar Peddi

Lei Shi

Anurupa Shrestha

Bruce Clapham

Phil B Cox

Todd N Soltwedel

Steve Latshaw

Charles A Wagner

Sean T Turner

Gao Yi

DanielD Caspi

Hutchinson Douglas K K

Krueger Allan C C

Douglas H Hutchinson

Sebel H Wagaw

Sachel V Patel

Kathy Sarris

Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R, R, and Rare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na1.7 and/or Na1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein G, L, Zand Zare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na1.7 and/or Na1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

(Indazol-4-yl) hexahydropyrrolopyrrolones and methods of use

Disclosed herein are modulators of TRPV3 of formula (I) wherein X, X, R, R, R, and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

TRPV3 modulators

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 antagonists

Growing community of inventors

Pleasant Prairie, WI, United States of America

Tammie K Jinkerson